Histone Methyltransferase SUV39H2 Supports Nasopharyngeal Carcinoma Cell Metastasis by Regulation of SIRT1

被引：1

作者：

You J. ^{[1
]}

Xue H. ^{[1
]}

Chao C. ^{[1
]}

Zhang Z. ^{[1
]}

Tan X. ^{[1
]}

Wang X. ^{[1
]}

Li H. ^{[1
]}

机构：

[1] Department of Otorhinolaryngology, The Third Affiliated Hospital of Soochow University, Jiangsu, Changzhou

来源：

Environmental Toxicology | 2024年 / 39卷 / 11期

关键词：

histone methyltransferase; metastasis; nasopharyngeal carcinoma; SIRT1; SUV39H2;

D O I：

10.1002/tox.24370

中图分类号：

学科分类号：

摘要：

Nasopharyngeal carcinoma (NPC) is a malignant tumor with high metastatic features originating from the nasopharynx. However, the underlying mechanism of Suppressor of variegation 3–9 homolog 2 (SUV39H2) in NPC remains poorly understood. RT-qPCR was carried out to examine SUV39H2 and SIRT1 expression in NPC tissues and cells. Kaplan–Meier method was utilized to evaluate the association between SUV39H2 level and overall survival. The function of SUV39H2 and SIRT1 in NPC cell viability, metastasis, and apoptosis was tested through CCK-8, transwell, and flow cytometry experiments. Here, it was uncovered that SUV39H2 level was augmented in NPC tissues and cells. Moreover, SUV39H2 expedited NPC cell viability, metastasis, and inhibited apoptosis, while SIRT1 addition reversed these impacts. Besides, SUV39H2 induced H3K9me3 enhancement to repress SIRT1 transcription via binding to SIRT1 promoter. Collectively, our results demonstrated upregulated SUV39H2 aggravated NPC tumorigenesis through SIRT1, which may offer a potential therapeutic target for NPC. © 2024 Wiley Periodicals LLC.

引用

页码：4974 / 4983

页数：9

共 34 条

[1] Yin L., Chen J., Ma C., Et al., Hsa_circ_0046263 Functions as a ceRNA to Promote Nasopharyngeal Carcinoma Progression by Upregulating IGFBP3, Cell Death and Disease, 11, 7, (2020)
[2] Chua M.L.K., Wee J.T.S., Hui E.P., Chan A.T.C., Nasopharyngeal Carcinoma, Lancet, 387, 10022, pp. 1012-1024, (2016)
[3] Chen Y.P., Chan A.T.C., le Q.T., Blanchard P., Sun Y., Ma J., Nasopharyngeal Carcinoma, Lancet, 394, 10192, pp. 64-80, (2019)
[4] Xu T., Tang J., Gu M., Liu L., Wei W., Yang H., Recurrent Nasopharyngeal Carcinoma: A Clinical Dilemma and Challenge, Current Oncology, 20, 5, pp. e406-e419, (2013)
[5] Blanchard P., Lee A., Marguet S., Et al., Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma: An Update of the MAC-NPC Meta-Analysis, The Lancet Oncology, 16, 6, pp. 645-655, (2015)
[6] You R., Cao Y.S., Huang P.Y., Et al., The Changing Therapeutic Role of Chemo-Radiotherapy for Loco-Regionally Advanced Nasopharyngeal Carcinoma From two/Three-Dimensional Radiotherapy to Intensity-Modulated Radiotherapy: A Network Meta-Analysis, Theranostics, 7, 19, pp. 4825-4835, (2017)
[7] He Y., Jing Y., Wei F., Et al., Long Non-Coding RNA PVT1 Predicts Poor Prognosis and Induces Radioresistance by Regulating DNA Repair and Cell Apoptosis in Nasopharyngeal Carcinoma, Cell Death & Disease, 9, 2, (2018)
[8] Hu J., Chen S., Kong X., Et al., Interaction Between DNA/Histone Methyltransferases and Their Inhibitors, Current Medicinal Chemistry, 22, 3, pp. 360-372, (2015)
[9] Zhao J., Li B., Ren Y., Et al., Histone Demethylase KDM4A Plays an Oncogenic Role in Nasopharyngeal Carcinoma by Promoting Cell Migration and Invasion, Experimental & Molecular Medicine, 53, 8, pp. 1207-1217, (2021)
[10] Li B., Zheng Y., Yang L., The Oncogenic Potential of SUV39H2: A Comprehensive and Perspective View, Journal of Cancer, 10, 3, pp. 721-729, (2019)

← 1 2 3 4 →